Core Viewpoint - A class action has been filed against Lantheus Holdings, Inc. for allegedly misleading investors regarding the competitive position of its key product, Pylarify, during a specified period [1][2]. Group 1: Allegations and Misleading Statements - The complaint alleges that Lantheus made materially false and misleading statements about Pylarify's competitive position, failing to accurately assess pricing and competitive dynamics [2][3]. - It is claimed that Lantheus did not properly disclose the implications of a price increase in early 2025, which created opportunities for competitive pricing and risked Pylarify's revenue and growth potential [2]. Group 2: Financial Impact and Stock Performance - On August 6, 2025, Lantheus announced disappointing results, revealing an 8.3% year-over-year decline in Pylarify's performance and significantly reduced growth expectations for fiscal year 2025 [4]. - Following this announcement, Lantheus' stock price dropped from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, marking a decline of approximately 28.8% in one day [4].

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Lantheus Holdings, Inc. ("Lantheus†or the "Company†) (NASDAQ: LNTH) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON LANTHEUS HOLDINGS, INC. (LNTH), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened. ...

RADNOR, Pa., Sept. 12, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH) on behalf of those who purchased or otherwise acquired Lantheus securities between February 26, 2025, and August 5, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is November 10, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered La ...

Core Viewpoint - The Lantheus Holdings, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misrepresented its revenue outlook and growth potential during a specific class period [1][3]. Company Overview - Lantheus develops, manufactures, and commercializes diagnostic and therapeutic products, particularly focusing on oncology, with its key product being Pylarify, a PET imaging agent for prostate cancer [2][3]. Allegations of the Lawsuit - The lawsuit claims that Lantheus executives created a false impression of the company's revenue outlook and growth while downplaying risks from competition and market dynamics [3]. - It is alleged that Lantheus's optimistic sales growth reports for Pylarify did not align with actual market conditions, leading to significant stock price declines following disappointing financial disclosures [3][4]. Financial Performance and Stock Impact - On May 7, 2025, Lantheus reported a year-over-year decrease in Pylarify sales and reduced its full-year growth projections, resulting in a stock price drop of over 23% [4]. - Following another disappointing announcement on August 6, 2025, which revealed an 8.3% year-over-year decline in Pylarify sales, the stock price fell nearly 29% [5]. Legal Process for Lead Plaintiff - Investors who purchased Lantheus securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [6].

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Lantheus Holdings, Inc. ("Lantheus†or the "Company†) (NASDAQ: LNTH) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN LANTHEUS HOLDINGS, INC. (LNTH), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal ri. ...

https://zlk.com/pslra-1/lantheus-holdings-inc-lawsuit-submission-form-2?prid=166642&wire=4 Accessibility StatementSkip Navigation NEW YORK, Sept. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus Holdings, Inc." or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lantheus Holdings, Inc. investors who were adversely affected by alleged securities fraud between February 2 ...

Core Viewpoint - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Lantheus Holdings, Inc. due to allegations of providing misleading business information to investors [1]. Company Overview - Lantheus Holdings, Inc. is a globally recognized company focused on the development, production, and distribution of advanced diagnostic and therapeutic products, with core expertise in oncology and cardiovascular care [3]. Alleged Wrongdoing - On August 6, 2025, Lantheus reported weaker-than-expected second-quarter results, missing earnings and revenue targets. The company cut its full-year 2025 revenue and EPS forecasts, citing tougher competition in the PSMA PET imaging market and strategic pullbacks from certain accounts [4]. - Revenue for the quarter fell to $378 million, down 4.1%, with PYLARIFY sales dropping 8.3% to $250.6 million, both below projections [4]. Market Reaction - Following the news of the disappointing results, Lantheus stock price fell by $20.76 per share, or 28.58%, closing at $51.87 per share on August 6, 2025 [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Lantheus Holdings, Inc. due to misleading statements regarding the competitive position of its product Pylarify, which led to significant financial losses for investors [4][6]. Group 1: Legal Investigation - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $75,000 in Lantheus between February 26, 2025, and August 5, 2025, to discuss their legal options [1]. - The firm has set a deadline of November 10, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Lantheus [4]. Group 2: Company Performance and Impact - The complaint alleges that Lantheus provided misleading statements about Pylarify's competitive position, which affected its pricing and growth potential [6]. - Investors began questioning Lantheus' public statements after the company reported first-quarter results below market expectations on May 7, 2025, particularly regarding Pylarify's performance [7]. - On August 6, 2025, Lantheus announced disappointing results and significantly reduced growth expectations for Pylarify, which had fallen 8.3% year-over-year, leading to a drastic cut in fiscal year 2025 growth projections [7]. - Following these revelations, Lantheus' stock price plummeted from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, marking a decline of approximately 28.8% in one day [8].

Sep 11, 2025 3:45 PM Eastern Daylight Time NASDAQ: LNTH: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Lantheus Holdings, Inc. Share RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Lantheus Holdings, Inc. ("Lantheus†) (NASDAQ: LNTH) on behalf of those who purchased or otherwise acquired Lantheus securities between February 26 ...

Core Viewpoint - Lantheus Holdings, Inc. is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1] Investigation Details - The investigation is being conducted by the Law Offices of Frank R. Cruz on behalf of investors [1] - The investigation follows the release of Lantheus's first quarter 2025 financial results on May 7, 2025 [1]